Animals also typically have shorter lives than humans, so a therapy could be studied over an animal’s entire lifetime and even over generations with its offspring.

Drug developers are increasing adoption of AI technologies for discovery and safety testing to get faster and cheaper results ...

Animals also typically have shorter lives than humans, so a therapy could be studied over an animal’s entire lifetime and even over generations with its offspring.

Reimagining alternatives to animal testing Artificial intelligence and organoid advances hold new promise for reducing the number of laboratory animals used in studies.

Dr. Vadim Jucaud's lab at the Terasaki Institute has developed a human vascularized liver cancer-on-a-chip model to evaluate ...

As regulators push to phase out animal testing, Charles River’s Steve Bulera notes that widespread implementation of alternative methods will “take time”.

FDA Announces Plan to Phase Out Animal Testing. Will That Work? Human organs-on-chips and organoids offer new alternatives to animals for drug development, but there is still a long way to go.

Dr. Barbara Natterson's work with animals became the focus of her new book, "Zoobiquity: What Animals Can Teach Us about Health and the Science of Healing," which she co-wrote with science writer ...

Animals also typically have shorter lives than humans, so a therapy could be studied over an animal’s entire lifetime and even over generations with its offspring.

Animals also typically have shorter lives than humans, so a therapy could be studied over an animal’s entire lifetime and even over generations with its offspring.

The FDA is phasing out animal testing requirements for drug approval, embracing AI and organoid alternatives to improve safety and reduce costs ...